Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease

✍ Scribed by Schreiber, S.; Reinisch, W.; Colombel, J.F.; Sandborn, W.J.; Hommes, D.W.; Robinson, A.M.; Huang, B.; Lomax, K.G.; Pollack, P.F.

• Book ID: 123316305
• Publisher: Oxford University Press
• Year: 2013
• Tongue: English
• Weight: 419 KB
• Volume: 7
• Category: Article
• ISSN: 1873-9946
• DOI: 10.1016/j.crohns.2012.05.015